The FDA has authorized the humanized monoclonal antibody lecanemab (Leqembi; Eisai) as a therapy for early Alzheimer’s disease (AD). In the last 20 years, it has been FDA-approved twice, but this is the first time through a conventional route. Lecanemab provided a substantial therapeutic effect in lowering cognitive and functional deterioration in AD patients, according to the phase 3 Clarity AD study data, which served as the foundation for the approval. Lecanemab acts by eliminating AD-related harmful amyloid-ß protofibrils. The majority of individuals eradicated their plaques from the brain after 18 months of therapy when the medication was evaluated in patients with amyloid evidence on PET or cerebrospinal fluid.

To know more: About the original article click here.